iBio, Inc. (IBIO): Price and Financial Metrics


iBio, Inc. (IBIO): $0.23

0.00 (1.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IBIO POWR Grades


  • Momentum is the dimension where IBIO ranks best; there it ranks ahead of 41.53% of US stocks.
  • The strongest trend for IBIO is in Growth, which has been heading up over the past 179 days.
  • IBIO ranks lowest in Quality; there it ranks in the 1st percentile.

IBIO Stock Summary

  • IBIO's price/sales ratio is 62.29; that's higher than the P/S ratio of 96.69% of US stocks.
  • As for revenue growth, note that IBIO's revenue has grown -29.86% over the past 12 months; that beats the revenue growth of only 5.6% of US companies in our set.
  • The volatility of iBio Inc's share price is greater than that of 95.09% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to iBio Inc, a group of peers worth examining would be BDR, MBII, RNLX, APPN, and DIOD.
  • IBIO's SEC filings can be seen here. And to visit iBio Inc's official web site, go to www.ibioinc.com.

IBIO Valuation Summary

  • In comparison to the median Healthcare stock, IBIO's price/sales ratio is 2326.32% higher, now standing at 92.2.
  • IBIO's price/sales ratio has moved up 59.3 over the prior 144 months.
  • IBIO's price/sales ratio has moved up 59.3 over the prior 144 months.

Below are key valuation metrics over time for IBIO.

Stock Date P/S P/B P/E EV/EBIT
IBIO 2021-08-31 92.2 2.6 -10.2 -9.2
IBIO 2021-08-30 92.2 2.6 -10.2 -9.2
IBIO 2021-08-27 92.2 2.6 -10.2 -9.2
IBIO 2021-08-26 88.6 2.5 -9.8 -8.8
IBIO 2021-08-25 91.5 2.6 -10.1 -9.1
IBIO 2021-08-24 91.5 2.6 -10.1 -9.1

IBIO Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -100.68%.
  • The 2 year revenue growth rate now stands at 162.6%.
  • Its 4 year price growth rate is now at -78.31%.
Over the past 55 months, IBIO's revenue has gone up $1,241,000.

The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.635 -34.608 -28.621
2021-09-30 2.172 -32.341 -24.873
2021-06-30 2.371 -30.064 -23.467
2021-03-31 3 -26.705 -27.121
2020-12-31 2.331 -23.142 -24.137
2020-09-30 1.94 -18.128 -41.33

IBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
  • IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
  • COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.

The table below shows IBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 0.383 -0.256
2021-03-31 0.024 0.836 -0.331
2020-12-31 0.023 1.000 -0.317
2020-09-30 0.027 1.000 -0.273
2020-06-30 0.032 1.000 -0.231
2020-03-31 0.036 1.000 -0.271

IBIO Stock Price Chart Interactive Chart >

Price chart for IBIO

IBIO Price/Volume Stats

Current price $0.23 52-week high $1.76
Prev. close $0.23 52-week low $0.22
Day low $0.23 Volume 1,833,100
Day high $0.25 Avg. volume 2,260,444
50-day MA $0.35 Dividend yield N/A
200-day MA $0.67 Market Cap 50.83M

iBio, Inc. (IBIO) Company Bio


iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.


IBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

IBIO Latest Social Stream


Loading social stream, please wait...

View Full IBIO Social Stream

Latest IBIO News From Around the Web

Below are the latest news stories about iBio Inc that investors may wish to consider to help them evaluate IBIO as an investment opportunity.

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended December 31, 2021 and provides a corporate update. “We are pleased to report that we have now added six new immuno-oncology assets to our pipeline in the six months since we announced our new drug discovery capabiliti

Yahoo | February 14, 2022

iBio Q2 2022 Earnings Preview

iBio (NYSE:IBIO) is scheduled to announce Q2 earnings results on Monday, February 14th, after market close. The consensus EPS Estimate is -$0.04 (flat Y/Y) and the consensus Revenue Estimate is $0.25M (-64.8% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates...

Seeking Alpha | February 13, 2022

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 second quarter financial results after market close on Monday, February 14, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Yahoo | February 7, 2022

iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease

iBio Inc (NYSE: IBIO ) received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company''s lead COVID-19 vaccine program. In light of the feedback received, the Company is moving forward with IND-enabling challenge studies for its second-generation … Full story available on Benzinga.com

Benzinga | January 26, 2022

iBio provides update on COVID-19 vaccine program IBIO-202

iBio <> provided an update on its lead COVID-19 vaccine program IBIO-202. The company said that according to feedback received from the U.S

Seeking Alpha | January 26, 2022

Read More 'IBIO' Stories Here

IBIO Price Returns

1-mo -31.49%
3-mo -32.45%
6-mo -65.90%
1-year -83.21%
3-year -71.25%
5-year -93.78%
YTD -58.11%
2021 -47.71%
2020 321.69%
2019 -66.80%
2018 -57.63%
2017 -55.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7146 seconds.